DLL3 and small cell lung carcinoma: While initial efforts to target DLL3 with an ADC failed, more recent efforts targeting DLL3 via T-cell engager strategies in SCLC have demonstrated remarkable success6,7 with recent approval by the FDA for treatment of relapsed SCLC.